Built-in Calculator Optimizes Continuous Veno-venous Hemofiltration Prescription and Improves Therapeutic Quality in Critically-ill Acute Kidney Injury Patients

Completed

• Conditions: Built-in Culculator; CVVH; Filtration Fraction
• Interventions: Device: Built-in calculator to calculate Filtration fraction

• Registration Number: NCT05638711
• Lead Sponsor: Taipei Medical University

Brief Summary

The goal of this observational study is to compare in ICU patients received CVVH treatment. The main questions it aims to answer are:

Control of Filtration fraction by built-in calculator

* Reduced filter clotting and prolong filter lifespan

* Improve patient mortality Participants will divided into before group and after group based on the day when built-in calculator for calculating Filtration fraction was utilized.

Researchers will compare before group to see if there were differences in clotting events, filter downtime, filter lifespan, mortality, etc.

Detailed Description

# built-in calculator for calculating Filtration fraction

* The calculator was built in prescription system since 2020/10/01

* providing tempt filtration fraction for operators to adjust CVVH dose

* the protocol of patient care didn't change between before and after group.

Study Timeline

• Study Start: 2019-01-01
• Primary Completion: 2021-12-31
• Study Completion: 2022-08-01
• Status Verified: 2022-11
• Study First Submitted: 2022-11-15
• Study First Submitted QC: 2022-11-27
• Last Update Submitted: 2022-11-27
• Study First Posted: 2022-12-06
• Last Update Posted: 2022-12-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• ICU patients received CVVH during 2019~2021 (3 years) in our hospital

Exclusion Criteria

• under age of 20, pregnant, or with HIV infection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
After group	Built-in calculator to calculate Filtration fraction	* Patient: ICU patients received CVVH between 2020/10/01 - 2021/12/31 (after utilization of built-in calculator) * received regular protocol of ICU patient care (same in two groups)

Primary Outcome Measures

Name	Time	Method
Mortality	30 days, 60 days, "through study completion, an average of 1.5 year" mortality in ICU and in Hospital	Patient death

Secondary Outcome Measures

Name	Time	Method
electrolytes_2	the last record received before CVVH (in an average of 1 hour), the first record received CVVH after 24 hours, the first record received after CVVH (in an average of 1 hour)	K
electrolytes_4	the last record received before CVVH (in an average of 1 hour), the first record received CVVH after 24 hours, the first record received after CVVH (in an average of 1 hour)	P
acid-base balance_2	the last record received before CVVH (in an average of 1 hour before CVVH treatment), the first record received CVVH after 24 hours (in an average of 1 hour after CVVH treatment), the first record received after CVVH (in an average of 1 hour after CVVH)	bicarbonate
Filter downtime	"through the complete treatment course hours, an average of 24 hours"	downtime between filter replacement
electrolytes_1	the last record received before CVVH (in an average of 1 hour), the first record received CVVH after 24 hours, the first record received after CVVH (in an average of 1 hour)
Filter clotting events	"through the complete treatment course hours, an average of 24 hours"	Filter clotting events
Filter lifespan	"through the complete treatment course hours, an average of 24 hours"	average treatment time per filter
acid-base balance_1	the last record received before CVVH (in an average of 1 hour before CVVH treatment), the first record received CVVH after 24 hours (in an average of 1 hour after CVVH treatment), the first record received after CVVH (in an average of 1 hour after CVVH)	pH
others_2	the last record received before CVVH (in an average of 1 hour before CVVH treatment), the first record received CVVH after 24 hours (in an average of 1 hour after CVVH treatment), the first record received after CVVH (in an average of 1 hour after CVVH)	platelet
electrolytes_3	the last record received before CVVH (in an average of 1 hour), the first record received CVVH after 24 hours, the first record received after CVVH (in an average of 1 hour)	Ca
others_1	the last record received before CVVH (in an average of 1 hour before CVVH treatment), the first record received CVVH after 24 hours (in an average of 1 hour after CVVH treatment), the first record received after CVVH (in an average of 1 hour after CVVH)	body temperature

Trial Locations

Locations (1)

Shuang-Ho Hospital; 🇨🇳 New Taipei City, Zhonghe District, Taiwan